Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006;38(8):654-63.
doi: 10.1080/00365540600617009.

HTLV-2 infection in injection drug users in King County, Washington

Affiliations

HTLV-2 infection in injection drug users in King County, Washington

Joseph R Zunt et al. Scand J Infect Dis. 2006.

Abstract

Human T-cell lymphotropic virus type 2 (HTLV-2) is endemic in injection drug users (IDU), and native American populations in the Americas. Transmission is associated with high-risk injection and sexual practices. A cohort of 2561 IDU in King County, Washington completed 2 study visits over 1 y. HTLV-2 infection was detected in 190 (7.4%) of 2561 IDU, and 13 (7.8 cases per 1000 person-y) incident infections occurred during the study. Prevalent infection was associated with female gender, non-white race, longer duration as IDU, having a tattoo, combined injection of heroin and cocaine, and with serologic evidence of hepatitis B and C infection. Seroconversion was more common in women, and was associated with African American race, heterosexual identity and longer duration as IDU. In conclusion, increased risk of HTLV-2 infection was associated with non-white race, and injection drug of choice, suggesting injection networks may play an important role in transmission of HTLV-2. The high correlation of HTLV-2 infection with HCV infection suggests the major route of transmission in IDU is via injection practices. Additional studies are needed to examine the clinical manifestations of HTLV-2 infection, as well as the clinical and virological manifestations of HTLV-2/HCV coinfection.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Feigal E, Murphy E, Vranizan K, Bacchetti P, Chaisson R, Drummond JE, et al. Human T-cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis. 1991;164:36–42. - PubMed
    1. Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992;326:375–80. - PubMed
    1. Schwebke J, Calsyn D, Shriver K, Saxon A, Kleyn J, Oluoch-Mitchell E, et al. Prevalence and epidemiologic correlates of human T-cell lymphotropic virus infection among intravenous drug users. J Infect Dis. 1994;169:962–7. - PubMed
    1. Thiede H, Harris NV, McGough JP, Roberts B, Khabbaz RF, Kaplan JE. Prevalence of HTLV types I and II among drug users in King County, Washington. West J Med. 1994;160:540–4. - PMC - PubMed
    1. Dourado I, Andrade T, Carpenter CL, Galvao-Castro B. Risk factors for human T-cell lymphotropic virus type I among injecting drug users in north-east Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz. 1999;94:13–8. - PubMed

Publication types

MeSH terms

LinkOut - more resources